GlassScriptPhysician profile
Nicole M Grilli
NPI 1710908694
$8,957.90
in general payments reported to CMS, 2019-2025
59 companies · $2,137 in 2025
The $2,137 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,042 · 2022: $1,470 · 2023: $2,101 · 2024: $2,207 · 2025: $2,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,354 · Education: $90.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,354.33 |
| Education | $90.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,574.29 | 2021-2025 | |
| Novo Nordisk INC | $1,098.83 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $717.17 | 2021-2025 | Airsupra, Breztri, Bevespi Aerosphere |
| Glaxosmithkline, LLC. | $472.21 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $344.80 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $282.34 | 2021-2025 | Xarelto, Spravato |
| Otsuka America Pharmaceutical, INC. | $274.63 | 2021-2025 | Rexulti |
| Astellas Pharma US INC | $274.24 | 2022-2025 | Veozah, Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $273.11 | 2022-2025 | Caplyta |
| Dexcom, INC. | $229.47 | 2021-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $227.77 | 2024-2025 | Voquezna |
| Vanda Pharmaceuticals INC. | $208.63 | 2024-2025 | Fanapt |
| Exact Sciences Corporation | $207.66 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $207.03 | 2021-2025 | |
| Corcept Therapeutics | $195.58 | 2022-2024 | Korlym |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Grilli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.